KRAS and neoplasm: In gastric and colorectal cancer (CRC) cell lines, abnormal activation of KRAS upregulates the expression of the glucose transporter‐1 (GLUT1), enabling tumor cells to adapt to low‐glucose conditions and ensuring their survival [20].